AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Merit Medical (MMSI) Launches New Inflation Device basixALPHA
by Zacks Equity Research
Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.
What You Need to Know From UnitedHealth's (UNH) Latest Outlook
by Zacks Equity Research
UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.
AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Boston Scientific (BSX) Posts Positive Post-Market Study Data
by Zacks Equity Research
The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.
Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?
by Zacks Equity Research
Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
by Zacks Equity Research
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.
Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio
by Zacks Equity Research
Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
Here's Why You Should Add McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Here's Why You Should Hold on to Abiomed (ABMD) Stock Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Merit Medical's (MMSI) New Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.
Why You Should Add UnitedHealth (UNH) to Your Portfolio Now
by Zacks Equity Research
The improvement of the economy is likely to support UnitedHealth's (UNH) commercial business recovery.
SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.